Antibody levels and immune memory 23 years after primary plasma-derived hepatitis B vaccination: Results of a randomized placebo-controlled trial cohort from China where endemicity is high
Antibody levels and immune memory 23 years after primary plasma-derived hepatitis B vaccination: Results of a randomized placebo-controlled trial cohort from China where endemicity is high
复制标题
初次血浆源性乙型肝炎疫苗接种 23 年后的抗体水平和免疫记忆：来自流行率较高的中国的随机安慰剂对照试验队列的结果
DOI：
10.1016/j.vaccine.2011.01.025
复制
发表时间：
2011-03-09
期刊：
影响因子：
5.5
通讯作者：
Zhang, Min
中科院分区：
文献类型：
--
作者：
Wu, Qian;Zhuang, Gui-Hua;Zhang, Min
B型肝炎疫苗的保护期仍不完全清楚。为了评估初级疫苗系列提供的长期保护，本研究再次招募了接种疫苗23年后先前随机安慰剂对照试验队列的所有受试者。261名生活在HBV高度流行国家的5-9岁健康儿童参加了初步试验，并接受了三剂血浆衍生疫苗或安慰剂。未接受任何B型肝炎免疫接种的主要安慰剂接受者在本研究中用作未接种疫苗的对照。在消除研究外早期加强剂量和疫苗的干扰后，48.1%（39/81）的疫苗接种者在第23年仍保持抗-HB滴度>= 10 mIU/mL，高于未接种疫苗的对照组的34.7%（26/75）（P = 0.088）。75-100%的接种者具有抗-HBs滴度
The duration of protection of hepatitis B vaccine remains incompletely understood. To assess the long-term protection provided by a primary vaccine series, the current study again recruited all subjects of a previous randomized placebo-controlled trial cohort 23 years after vaccination. Two hundred and sixty-one healthy children aged 5-9 years living in a highly HBV-endemic country were enrolled in the primary trial and received three doses of plasma-derived vaccine or placebo. The primary placebo receivers who did not receive any immunization against hepatitis B were used as non-vaccinated controls in the current study. After eliminating the interference of an early booster dose and vaccines outside the study, 48.1% (39/81) vaccinees still maintained anti-HBs titers >= 10 mIU/mL at Year 23, higher than 34.7% (26/75) in non-vaccinated controls (P = 0.088). 75-100% of vaccinees with anti-HBs titer